Literature DB >> 24381429

Correlation of levels of IL-6 with tumor burden and receptor status in patients of locally advanced carcinoma breast.

Binita Goswami1, Pankaj Mittal2, Nikhil Gupta3.   

Abstract

Inflammatory pathways have garnered considerable interest in the recent past as an important mediator of the molecular mechanisms leading to carcinogenesis. The present study was conducted to evaluate the correlation of levels of IL-6 with tumor burden and receptor status in patients of locally advanced carcinoma breast. This prospective study was conducted by the collaborative efforts of the departments of Surgery and Biochemistry, Maulana Azad Medical College and associated Lok Nayak Hospital and GB Pant Hospitals, New Delhi. The study population comprised of 30 cases of locally advanced breast carcinoma recruited from the surgical outpatient department. The various parameters that were evaluated include detailed clinico-pathological profile and IL-6 levels. Tissue specimens received after surgeries were examined for the various characteristics indicative of tumor prognosis. Majority of the patients was in the age group of 41-50 years and was postmenopausal. The serum level of IL-6 increased as the disease progressed from T3N1M0 to T4dN2M0 (41.4 ± 31.9 vs. 164.0 ± 31.1 pg/ml respectively). There was significant correlation of IL-6 levels with lymph node involvement, tumor grade, mitotic index and adipose tissue invasion. Emerging molecular markers are being investigated for breast cancer prognosis assessment and prediction of response to chemotherapy including selection of best possible treatment modality. Our study showed that there is progressive increase in IL-6 levels as the stage of disease progresses.

Entities:  

Keywords:  Carcinoma breast; IL-6; Inflammation

Year:  2012        PMID: 24381429      PMCID: PMC3547449          DOI: 10.1007/s12291-012-0234-7

Source DB:  PubMed          Journal:  Indian J Clin Biochem        ISSN: 0970-1915


  14 in total

1.  Interleukin-6 signaling regulates anchorage-independent growth, proliferation, adhesion and invasion in human ovarian cancer cells.

Authors:  Yue Wang; Lingzhi Li; Xiaoqin Guo; Xin Jin; Weijia Sun; Xiaolei Zhang; Rui Cheng Xu
Journal:  Cytokine       Date:  2012-05-15       Impact factor: 3.861

2.  IL6-mediated suppression of miR-200c directs constitutive activation of inflammatory signaling circuit driving transformation and tumorigenesis.

Authors:  Matjaz Rokavec; Weilin Wu; Jun-Li Luo
Journal:  Mol Cell       Date:  2012-02-23       Impact factor: 17.970

3.  Reduction in serum IL-6 after vacination of breast cancer patients with tumour-associated antigens is related to estrogen receptor status.

Authors:  X P Jiang; D C Yang; R L Elliott; J F Head
Journal:  Cytokine       Date:  2000-05       Impact factor: 3.861

4.  Locally Advanced Breast Cancer.

Authors: 
Journal:  Oncologist       Date:  1996

5.  TNF-alpha, IL-6 and their soluble receptor serum levels and secretion by neutrophils in cancer patients.

Authors:  E Jabłońska; M Kiluk; W Markiewicz; L Piotrowski; Z Grabowska; J Jabłoński
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2001       Impact factor: 4.291

6.  An analysis of serum interleukin-6 levels to predict benefits of medroxyprogesterone acetate in advanced or recurrent breast cancer.

Authors:  R Nishimura; K Nagao; H Miyayama; M Matsuda; K Baba; Y Matsuoka; H Yamashita; M Fukuda; T Mizumoto; R Hamamoto
Journal:  Oncology       Date:  2000-08       Impact factor: 2.935

Review 7.  Significance of interleukin-6 (IL-6) in breast cancer (review).

Authors:  Heike Knüpfer; Rainer Preiss
Journal:  Breast Cancer Res Treat       Date:  2006-08-23       Impact factor: 4.872

8.  Tumour necrosis factor-alpha, interleukin-6, and fasting serum insulin correlate with clinical outcome in metastatic breast cancer patients treated with chemotherapy.

Authors:  Hakan Bozcuk; Gülcan Uslu; Mustafa Samur; Mustafa Yildiz; Tomris Ozben; Mustafa Ozdoğan; Mehmet Artaç; Hasan Altunbaş; Ilhan Akan; Burhan Savaş
Journal:  Cytokine       Date:  2004 Jul 21-Aug 7       Impact factor: 3.861

Review 9.  Cellular and molecular pathways linking inflammation and cancer.

Authors:  Chiara Porta; Paola Larghi; Monica Rimoldi; Maria Grazia Totaro; Paola Allavena; Alberto Mantovani; Antonio Sica
Journal:  Immunobiology       Date:  2009-07-17       Impact factor: 3.144

10.  Concentration of interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients.

Authors:  L Kozłowski; I Zakrzewska; P Tokajuk; M Z Wojtukiewicz
Journal:  Rocz Akad Med Bialymst       Date:  2003
View more
  3 in total

Review 1.  Pre-treatment effects of peripheral tumors on brain and behavior: neuroinflammatory mechanisms in humans and rodents.

Authors:  Andrew Schrepf; Susan K Lutgendorf; Leah M Pyter
Journal:  Brain Behav Immun       Date:  2015-05-06       Impact factor: 7.217

2.  Digitoxin Inhibits Epithelial-to-Mesenchymal-Transition in Hereditary Castration Resistant Prostate Cancer.

Authors:  Bette S Pollard; Mark A Suckow; William R Wolter; Joshua M Starr; Ofer Eidelman; Clifton L Dalgard; Parameet Kumar; Sharmistha Battacharyya; Meera Srivastava; Roopa Biswas; Matthew D Wilkerson; Xijun Zhang; Qingfeng Yang; Harvey B Pollard
Journal:  Front Oncol       Date:  2019-08-02       Impact factor: 6.244

3.  Significance of Interleukin-6 in Papillary Thyroid Carcinoma.

Authors:  Toral P Kobawala; Trupti I Trivedi; Kinjal K Gajjar; Darshita H Patel; Girish H Patel; Nandita R Ghosh
Journal:  J Thyroid Res       Date:  2016-03-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.